Techno Medica Co., Ltd. (6678) AI Stock Analysis

• Market Cap: ¥19.73B
• Dividend Yield: 3.02%
• Average Volume (3M): 5.40K
• Price to Earnings (P/E): 15.1
• Beta (1Y): 0.59
• Revenue Growth: -4.36%
• EPS Growth: -14.92%
• Country: JP
• Employees: 237
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 37.13
• Shares Outstanding: 8,760,000
• 10 Day Avg. Volume: 4,730
• 30 Day Avg. Volume: 5,400
• PEG Ratio: -0.75
• Price to Book (P/B): 0.84
• Price to Sales (P/S): 1.23
• P/FCF Ratio: 12.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 78 Outperform
• Price Target: ¥2,817.00 ▲(25.48% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is primarily driven by very strong balance-sheet quality (zero debt) and overall solid financial performance, tempered by recent revenue decline and margin compression. Technicals add support due to a clear uptrend and positive momentum indicators, while valuation is reasonable with a mid-teens P/E and ~3% yield.

Positive Factors

Balance-sheet strength (zero debt)

Zero debt materially lowers financial risk and provides durable financial flexibility. Over a 2–6 month horizon this supports resilient operations, ability to fund capex, R&D or dividends without refinancing, and greater capacity to withstand cyclical weakness or pursue strategic bolt-on investments.

Negative Factors

Revenue decline in FY2025

A nearly 4% revenue decline signals emerging demand weakness or market share pressure. If this trend persists it constrains scale benefits, limits ability to invest in R&D and commercial expansion, and can weaken long-term top-line growth prospects in a competitive med‑tech market.

Techno Medica Co., Ltd. Business Overview & Revenue Model

Company Description

Techno Medica Co., Ltd. engages in the research and development, manufacture, sale, import, and export of in-vitro diagnostic analyzers in Japan. The company offers test tube preparation, automatic urine aliquot, RFID specimen management, and RFID...

Read more

Techno Medica Co., Ltd. engages in the research and development, manufacture, sale, import, and export of in-vitro diagnostic analyzers in Japan. The company offers test tube preparation, automatic urine aliquot, RFID specimen management, and RFID...

How the Company Makes Money

null...

Techno Medica Co., Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	9.66B	9.91B	10.28B	9.37B	9.70B	9.04B
Gross Profit	4.73B	4.88B	5.10B	4.59B	4.78B	4.42B
EBITDA	1.15B	1.40B	1.95B	1.76B	1.96B	1.71B
Net Income	847.54M	1.00B	1.35B	1.15B	1.28B	1.15B
Balance Sheet
Total Assets	16.66B	17.94B	17.43B	19.44B	18.51B	17.55B
Cash, Cash Equivalents and Short-Term Investments	8.67B	9.06B	8.59B	11.75B	11.52B	10.14B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	2.73B	3.55B	3.62B	3.06B	2.86B	2.59B
Stockholders Equity	13.93B	14.39B	13.82B	16.39B	15.65B	14.96B
Cash Flow
Free Cash Flow	0.00	952.67M	1.10B	748.50M	2.00B	791.50M
Operating Cash Flow	0.00	977.53M	1.14B	887.24M	2.06B	825.41M
Investing Cash Flow	0.00	-32.34M	-100.72M	-155.37M	2.49B	-153.68M
Financing Cash Flow	0.00	-470.16M	-4.21B	-505.09M	-598.64M	-415.34M

Techno Medica Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2245.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6678, the sentiment is Neutral. The current price of 2245 is below the 20-day moving average (MA) of 2336.06, below the 50-day MA of 2362.85, and above the 200-day MA of 2048.45, indicating a neutral trend. The MACD of -13.42 indicates Positive momentum. The RSI at 47.82 is Neutral, neither overbought nor oversold. The STOCH value of 54.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:6678.

Techno Medica Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6678	78 Outperform	¥19.73B	15.12	―	3.02%	-4.36%	-14.92%
4549	68 Neutral	¥114.23B	26.70	―	2.31%	4.36%	79.43%
7963	67 Neutral	¥9.22B	10.32	―	1.89%	9.47%	37.35%
6849	65 Neutral	¥255.67B	36.37	―	1.92%	4.31%	96.31%
7600	63 Neutral	¥14.51B	14.76	―	3.12%	3.59%	-163.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6523	51 Neutral	¥136.36B	28.05	2.42%	3.73%	0.04%	―

Techno Medica Co., Ltd. Corporate Events